Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 9/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 1/20 | 0.40 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.40 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21679708 | 1.00 | LMNA (0.46) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL21679730 | 1.00 | LMNA (0.46) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL21679715 | 1.00 | LMNA (0.46) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL1354834 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL9354133 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL10703302 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL8205797 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL20873213 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL7044918 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 | |
| SCHEMBL182466 | 0.97 | LMNA (0.48) | LMNATSHRALDH1A1HSD17B10MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10808003-B2 | Amphipathic molecule based on tandem malonate and use thereof | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-10-20 | — | — | US | disclosed |
| US-20200048297-A1 | NOVEL AMPHIPATHIC MOLECULE BASED ON TANDEM MALONATE AND USE THEREOF | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2020-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200048297-A1 | NOVEL AMPHIPATHIC MOLECULE BASED ON TANDEM MALONATE AND USE THEREOF | MAL2, LNPK, ANXA6 | LMNA 2907/4885TSHR 3261/4885ALDH1A1 4609/4885 |
| US-10808003-B2 | Amphipathic molecule based on tandem malonate and use thereof | MAL2, LNPK, TSPO | LMNA 3053/4885TSHR 2946/4885ALDH1A1 4535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.